Evidence map›Paper›PMID 42482451›Full record

ArticleThe Journal of pathology2026

Functional validation of driver mutation-specific uveal melanoma biomarkers: role of COL9A3 in cancer cell plasticity.

Qcc van den Bosch, R M Verdijk, H Fadlelseed, Tpp van den Bosch, S Owens, S Kennedy, E Kilic, E Brosens

Abstract read
In one paragraph

Article in The Journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qcc van den BoschDepartment of Ophthalmology, Erasmus MC, Rotterdam, The Netherlands.ORCID https://orcid.org/0009-0009-3675-6006
R M VerdijkDepartment of Pathology, Erasmus MC Cancer Institute University Medical Center, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0003-1437-214X
H FadlelseedNational Ophthalmic Pathology Laboratory, Royal Victoria Eye and Ear Hospital and Research Foundation, Dublin, Ireland.ORCID https://orcid.org/0009-0001-8850-5163
Tpp van den BoschDepartment of Pathology, Erasmus MC Cancer Institute University Medical Center, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-7223-4565
S OwensNational Ophthalmic Pathology Laboratory, Royal Victoria Eye and Ear Hospital and Research Foundation, Dublin, Ireland.ORCID https://orcid.org/0000-0001-5420-4154
S KennedyNational Ophthalmic Pathology Laboratory, Royal Victoria Eye and Ear Hospital and Research Foundation, Dublin, Ireland.ORCID https://orcid.org/0000-0002-4948-5374
E KilicDepartment of Ophthalmology, Erasmus MC, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-6867-3792
E BrosensDepartment of Clinical Genetics, Erasmus MC Cancer Institute University Medical Center, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0001-8235-4010

Funding

Algemene Nederlandse Vereniging ter voorkoming van Blindheid 2019-07Combined Ophthalmic Research Rotterdam (CORR) 6.2.0Landelijke Stichting voor Blinden en Slechtzienden 2019-7Rotterdamse Stichting Blindenbelangen HV/AB/B20200043
6 · The paper itself

Abstract

Uveal melanoma (UM) is a deadly ocular malignancy with well-described genetic alterations that predict disease outcome. However, our current understanding of the biological underpinnings of high-risk uveal melanoma progression remains relatively limited. Using RNA expression profiles from 250 patients with UM, we identified 12 novel biomarkers associated with high-risk UM, with protein expression level validation of the top two candidates: the transcriptional regulator RBFOX2 and matrix protein COL9A3. Moreover, we investigated the functional contribution of COL9A3 via its overexpression in EIF1AX

Indexed as

Biomarkers, TumorCell PlasticityMelanomaMutationUveal NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationEukaryotic Initiation Factor-1FemaleGene Expression Regulation, NeoplasticHumansRNA Splicing FactorsTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1 protein, humanBiomarkers, TumorEukaryotic Initiation Factor-1eukaryotic peptide initiation factor-1ARNA Splicing FactorsTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1 mutationbiomarkerscell plasticityCOL9A3tumor microenvironmentuveal melanomazebrafish xenograft

Identifiers

PMID42482451
PMCPMC13576891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.